Skip to main content

Drug Interactions between Crysti-12 and Gen-K

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

potassium chloride cyanocobalamin

Applies to: Gen-K (potassium chloride) and Crysti-12 (cyanocobalamin)

Limited data suggest that orally administered potassium chloride may decrease the gastrointestinal absorption of vitamin B12. The mechanism is believed to be a reduction in ileal pH by potassium chloride, which significantly decreases the activity of intrinsic factor that is necessary for vitamin B12 absorption. However, the interaction should rarely lead to clinically significant deficiency because the body (primarily the liver) usually has a copious supply of vitamin B12 that can sustain a person for several years in the absence of adequate intake. As for the treatment of B12 deficiency-related anemia, non-oral routes of administration (e.g., parenteral, intranasal, sublingual) are generally preferred, which would bypass the potential interaction.

References

  1. Palva IP, Salokannel SJ, Timonen T, Palva HL "Drug-induced malabsorption of vitamin B 12 . IV. Malabsorption and deficiency of B 12 during treatment with slow-release potassium chloride." Acta Med Scand 191 (1972): 355-7

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer